Sysmex (OTCMKTS:SSMXY) Shares Gap Up – Should You Buy?

Sysmex Corporation ADR (OTCMKTS:SSMXYGet Free Report)’s stock price gapped up prior to trading on Friday . The stock had previously closed at $10.30, but opened at $11.11. Sysmex shares last traded at $10.59, with a volume of 5,151 shares.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on the company. The Goldman Sachs Group raised Sysmex from a “hold” rating to a “buy” rating in a research report on Thursday, October 9th. Zacks Research upgraded Sysmex from a “strong sell” rating to a “hold” rating in a research report on Thursday, August 14th. One equities research analyst has rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to MarketBeat, Sysmex presently has an average rating of “Moderate Buy”.

Get Our Latest Research Report on SSMXY

Sysmex Stock Performance

The company has a quick ratio of 2.49, a current ratio of 3.37 and a debt-to-equity ratio of 0.12. The stock has a market capitalization of $6.68 billion, a P/E ratio of 21.21 and a beta of 1.16. The business has a fifty day moving average price of $12.19 and a 200-day moving average price of $15.03.

Sysmex (OTCMKTS:SSMXYGet Free Report) last announced its earnings results on Wednesday, November 5th. The company reported $0.16 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.16. The business had revenue of $826.60 million for the quarter, compared to analysts’ expectations of $880.80 million. Sysmex had a return on equity of 10.20% and a net margin of 9.35%. On average, sell-side analysts expect that Sysmex Corporation ADR will post 0.57 EPS for the current year.

About Sysmex

(Get Free Report)

Sysmex Corporation engages in the development, manufacture, and sale of diagnostic instruments, reagents, and related software in Japan. It offers three-part and five-part white blood cell differentiation instruments for use in hematology; and transport systems for high-volume testing in labs. The company also provides automated urine particle analyzers; automated blood coagulation analyzers; automated immunochemistry systems, which perform assays on minute sample quantities, as well as reagents to test for infectious disease and tumor markers; and flow cytometers to perform analysis in diagnosing leukemia, malignant lymphoma, and HIV/AIDS.

See Also

Receive News & Ratings for Sysmex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sysmex and related companies with MarketBeat.com's FREE daily email newsletter.